Eye­ing block­buster mi­graine mar­ket, Al­ler­gan un­loads sec­ond set of pos­i­tive PhI­II re­sults for ubro­gepant

Al­ler­gan $AGN rolled out its sec­ond wave of pos­i­tive Phase III da­ta for its oral mi­graine drug ubro­gepant, which nailed its end­points in the high­er …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.